SAN1 N Stock Overview
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1,629.20 |
| 52 Week High | €1,978.38 |
| 52 Week Low | €1,609.59 |
| Beta | 0.43 |
| 11 Month Change | 0% |
| 3 Month Change | 1.22% |
| 1 Year Change | -11.35% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| SAN1 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -0.9% |
| 1Y | -11.4% | -20.7% | -4.7% |
Return vs Industry: SAN1 N exceeded the MX Pharmaceuticals industry which returned -26.5% over the past year.
Return vs Market: SAN1 N underperformed the MX Market which returned 1% over the past year.
Price Volatility
| SAN1 N volatility | |
|---|---|
| SAN1 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: SAN1 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SAN1 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 91,573 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Sanofi Fundamentals Summary
| SAN1 N fundamental statistics | |
|---|---|
| Market cap | Mex$2.15t |
| Earnings (TTM) | Mex$168.79b |
| Revenue (TTM) | Mex$850.82b |
12.7x
P/E Ratio2.5x
P/S RatioIs SAN1 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAN1 N income statement (TTM) | |
|---|---|
| Revenue | €45.70b |
| Cost of Revenue | €13.92b |
| Gross Profit | €31.78b |
| Other Expenses | €22.71b |
| Earnings | €9.07b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 01, 2024
| Earnings per share (EPS) | 7.23 |
| Gross Margin | 69.54% |
| Net Profit Margin | 19.84% |
| Debt/Equity Ratio | 28.8% |
How did SAN1 N perform over the long term?
See historical performance and comparison